The company was founded by Dr. Lorena Betancor, a professor of Protein Technology and researcher; Dr. Valeria Grazú, a researcher at INMA and professor of Nanobiotechnology at ORT; and Dr. Jesús Martínez de la Fuente, a researcher at INMA.
An innovative technology
Promethenz is developing a technology based on enzymatic nanohybrids that can be activated by external magnetic fields, aimed at treating solid tumors, particularly pancreatic cancer.
After taking first place in the Uruguayan round, the startup will participate in the competition's grand finale, which will take place on December 3 in Buenos Aires. There, it will present its proposal to key figures in the entrepreneurial ecosystem and investors from the region.
The Uruguayan edition of the competition was supported by the Universidad ORT Uruguay, URUCAP, and Distrito El Globo.